We improve the safety of patients, clinics, their staff and the environment by transforming the way infection prevention practices are understood and conducted and introducing innovative technologies that deliver improved standards of care.
We are an innovator in infection prevention. Our unique, automated trophon® EPR high level disinfection (HLD) device is paving the way around the world in setting a new standard of care in ultrasound probe disinfection practices.
trophon is a global solution for reducing cross contamination between patients and reducing the spread of Healthcare Acquired Infections (HAIs).
With a growing trend around the world towards stricter ultrasound probe reprocessing guidelines, traditional systems have been falling behind in their ability to meet today’s demanding requirements. The cutting edge technology used in trophon has really disrupted the disinfection market and is the first major innovation in ultrasound probe HLD in more than 20 years.
Nanosonics has broken new ground in completely re-thinking ultrasound reprocessing. trophon is a breakthrough solution across three core areas: Safety, Versatility, and Simplicity.
Safety – trophon sets a new benchmark in protecting patients, staff and the environment from the dangerous hazards of traditional chemical soaking methods; Reduces Risk
Versatility – trophon is compact and self-contained, allowing HLD to be conducted just about anywhere you need it. No complex installation and with an ever-growing probe compatibility list of over 1,000 ultrasound probes across all manufacturers – trophon has your needs covered; Reduces Cost
Simplicity – trophon is simple to operate and with minimal training new staff members can be delivering consistent HLD of their ultrasound probes with confidence. trophon’s powerful but simple traceability system ensures all of your reprocessing activities are documented and audit ready; Increase Compliance
Our story at a glance
FOUNDED IN 2001 and head-quartered in Sydney, Australia, Nanosonics listed on the Australian Securities Exchange (NAN) in 2007.
IN 2009, we launched trophon, our unique, automated technology for the HLD of intracavity and surface ultrasound probes.
IN MARCH 2015, Nanosonics was included in the Australian Stock Exchange ASX300 Index (Australia’s top 300 companies by market capitalisation). The following year, the company joined the Australian Stock Exchange ASX200 Index (Australia’s top 200 companies by market capitalisation).
TODAY we have offices in North America, Canada, the United Kingdom and Europe, employing more than 150 people.
Our technology is now available in North America, Canada, the United Kingdom, Ireland, Germany, France, Belgium, Italy, Denmark, Russia, Singapore, Hong Kong, Australia and New Zealand.
Along the way we have formed channel partnerships with leading global brands for the distribution of trophon, supported by our expert team who understand infection prevention challenges.
We have a highly experienced team of professionals committed to providing HLD solutions for ultrasound probe use and have developed a deep understanding of our customers’ needs in infection prevention. Alongside our passion for product innovation, we are dedicated to research and are continually evolving trophon’s superior efficacy over other current disinfection methods.